Clinical trial

SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer

NCT07619911

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention SHR-1701 combined with platinum-doublet chemotherapy induction therapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention SHR-1701 consolidation therapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Platinum-doublet chemotherapy Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention radiotherapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-07-01

PhasePHASE2

Conditions

NSCLC Stage IIIunresolved

SHR-1701unresolved

Chemoradiotherapyunresolved

Interventions

SHR-1701 combined with platinum-doublet chemotherapy induction therapyDRUG

SHR-1701 consolidation therapyDRUG

Platinum-doublet chemotherapyDRUG

radiotherapyRADIATION

Sponsors & collaborators

Fudan Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07619911 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.